The use of topoisomerase inhibitors has been associated with the development of secondary malignancies, suggesting that these agents can induce DNA damage that may be persistent. We have investigated the effect of short exposures (Ͼ3 days) to low etoposide concentrations (LC-etoposide, 0.01-0.04 M) on the ability of leukaemic cells to initiate apoptosis. Results showed that although LC-etoposide had no effect on cell growth characteristics, the pre-culture of cells with LC-etoposide conferred resistance to subsequent exposure to cytotoxic concentrations of etoposide (0.3 M etoposide in HL60 on day 3: %V: 95.2 ± 1.6% vs 60.3 ± 12.1% in control cells with no preculture, and %A: 5.1 ± 0.2 vs 19.0 ± 0.7%; P Ͻ 0.001). This effect was still observed 4 weeks after the initial drug exposure. Associated with these observations was a three-fold increase in genetic instability and a reduction in induced bax protein levels. The anti-cytotoxic effect was also shown to be specific to topoisomerase II (topo II) inhibitors, as the pre-culture of cells with a low doxorubicin concentration also induced resistance, while low cisplatin concentrations did not. The persistence of these alterations in cellular processes following an initial exposure to topo II inhibitors suggests a DNA-based mechanism, and highlights the existence of drug/target interactions even at very low drug concentrations.
Introduction
Etoposide has a broad range of anti-neoplastic activity, and is one of the most widely used drugs in the treatment of malignant diseases in children and adults. 1 It is schedule dependent with some advantages when used in longer schedules compared to shorter ones. 1, 2 Unfortunately, its use has been associated with an increased risk of secondary leukaemias, especially AML. [3] [4] [5] [6] Most of these early reports of secondary AML followed treatment with a high cumulative dose of etoposide 5 g/m 2 , but the monitoring of a number of clinical trials using etoposide or teniposide did not find a dose effect. 6 Moreover, secondary AML has been reported in patients following exposure to a cumulative dose of just 2 g/m 2 , suggesting that even the use of relatively low-dose etoposide could also be associated with the development of secondary disease. 7 Etoposide cytotoxicity is mediated by DNA topo II, which is a ubiquitously expressed nuclear enzyme required to maintain the topology of DNA, particularly during chromosomal recombination, replication and transcription. 8 The mechanism of etoposide inhibition of topo II is such that the enzyme is still able to cleave DNA, but re-ligation is inhibited by the stabilisation of covalent enzyme-DNA intermediates by the drug, resulting in double-stranded DNA breaks and cell death. 9 While there is good correlation between accumulation of these double-strand breaks and the induction of cell death, there is little information regarding the steps between these two events. 10 Etoposide is also a potent clastogenic agent, increasing the frequency of sister chromatid exchanges (SCEs), as well as causing a spectrum of chromosomal abnormalities such as translocations and deletions. [10] [11] [12] It has been suggested that these chromosomal aberrations are inseparable from the more relevant anti-neoplastic effects -cytotoxicity being inextricably linked to the induction of genetic changes. 13 In fact, it has been speculated that the topo II-DNA complexes induced by etoposide may function to specifically increase SCEs and illegal chromosomal recombinations. The resulting disruption to the normal genotype, specifically the loss of essential genes, ultimately leads to cell death. 11 This induction of chromosome abnormalities, particularly illegitimate recombinations, are thought to be the mechanism underlying the leukaemogenic potential of etoposide, by promoting the activation of proto-oncogenes capable of modifying a variety of cellular processes such as apoptosis, proliferation and differentiation. The sites at which etoposide can induce genetic changes are non-random, 14 and probably coincide with preferred topoisomerase II (topo II) cleavage sites. 15 Cytogenetic analysis has shown the chromosomal aberrations that frequently involve chromosomes 11, 17 and 19, invariably cause disruption to the genes that are located on these chromosomes. Specifically, most cases of etoposideinduced secondary AML have characteristic 11q23 rearrangements that interrupt the MLL gene (also termed ALL1 and HRX). 16, 17 Although cases of secondary AML seem to be doseindependent, the number of chromosomal aberrations does appear to be dose-dependent. However, the relationship between these two remains unclear, since the induction of SCEs and DNA abnormalities do not necessarily lead to a transformation of the genotype. 13 Etoposide is extensively protein bound, with only 5% free in the blood in vivo, and as a consequence, intracellular concentrations vary between patients and can be very low. 18 The effects of these potentially low concentrations of etoposide on cells have not been fully investigated, and the possible significance of these concentrations in leukaemogenesis has never been fully examined. As part of our on-going studies of etoposide scheduling, we have investigated whether initial exposure to very low concentrations of etoposide alters the subsequent apoptotic and differentiation responses of leukaemic cells to cytotoxic agents. We also examined whether these low concentrations of drug induce persistent DNA damage.
Materials and methods

Cell culture
All leukaemic cell lines were maintained in RPMI-1640 medium supplemented with 10% FBS and 1% Leukemia penicillin/streptomycin, in a humidified atmosphere with 5% CO 2 in air at 37°C.
Cytotoxicity assays using cells pre-treated with low concentrations of etoposide
CEM and HL60 cells (2 × 10 5 cell/ml) were reset in fresh medium for 5 days in the presence of etoposide (0-0.4 M). Aliquots were removed daily for analysis of cell number and cell viability. The highest concentration of etoposide that had no significant effect on cell growth, viability and cell cycle distribution was deemed the low concentration of etoposide (LC-etoposide), which was 0.01 M for both cell lines.
The effect of LC-etoposide was investigated by initially culturing cells with LC-etoposide and then with cytotoxic concentrations of etoposide or cisplatin. Specifically, cells (2 × 10 5 cell/ml) were reset in fresh medium and cultured with one of the 6 day schedules shown in Table 1 . Aliquots were removed daily for cell counts, cell cycle analysis and assessment of viability.
To investigate the importance of topo II, CEM and HL60 cells were cultured in drug schedules that included a 3 day pre-exposure to a low concentration of either doxorubicin or cisplatin. By using similar methods to those described earlier, the low concentration of either drug was ascertained as 0.02 M and 0.2 M, respectively. These primed cells were then exposed to cytotoxic concentrations (IC 50 ) of either etoposide (0.3 M) or cisplatin (10 M) for a further 3 days before assessment of cell number and viability.
Production of CEM-L and HL60-L sublines
The CEM-L and HL60-L sublines were produced by culturing CEM and HL60 cells in 0.01 M etoposide for only 5 days before washing and resetting in drug-free medium to allow for recovery. The resultant CEM-L and HL60-L cells were then maintained and propagated hence in drug-free medium. Aliquots were removed from these stock cultures, and subsequent cytotoxicity investigations were performed using these sublines.
To investigate the cytotoxic effect of typical concentrations of standard chemotherapeutic agents, these sublines were cultured continuously for 4 days with cytotoxic concentrations (ϷIC 50 ) of either etoposide (0.3 M) or cisplatin (10 M), and cell counting and flow cytometric analysis performed daily. Additional experiments were also performed where each subline was cultured with hyper-toxic concentrations of etoposide (0.6 and 0.9 M), in place of the standard 0.3 M. 
DNA analysis
The distinct phases of the cell cycle were distinguished by flow cytometry, according to methods described previously. 19 Acquisition of data was performed within 1 h using a Becton Dickinson FACScan machine (Cowley, UK). Ten thousand cells were analysed for each data point, and the percentages of cells in sub-G1 (apoptotic fraction -cells with a reduced PI stain but similar morphology), 20 G1, S and G2/M phases were determined using a cell cycle analysis program (WinMDI 2.4).
Assessment of SCE frequency
Cells (5 × 10 5 ) were cultured in 10 ml RPMI medium with 10 mM bromodeoxyuridine (BrdU; Sigma (Poole, UK)) and incubated in the dark at 37°C for 24 h. Etoposide (0-1 M) was then added to the cultures and incubated for a further 24 h. Preparation of samples for the assessment of SCE frequency was then performed as described previously. 12 
Cytogenetic analyses
Chromosomal analyses of CEM, HL60, CEM-L and HL60-L cells were performed by the Cytogenetics Department of the Cancer Research UK Medical Oncology Laboratory at St Bartholomew's Hospital according to conventional cytogenetic procedures. Review of karyotypes for each sample was performed by at least two members of the department.
Chromosome analyses were performed using G-banding techniques on approximately 20 metaphases. Clonal abnormalities were defined as two or more cells with the same additional whole chromosome or chromosome rearrangement, or three or more cells with the same chromosome missing, while random structural aberrations (RSAs) were defined as chromosomal abnormalities present in only one or two metaphase cells, which did not affect the definition of the cell. A simple measure of genetic damage was achieved by the estimation of the percentage of metaphase spreads that exhibited RSAs. Karyotypes were described according to the International System for Human Cytogenetics Nomenclature, 21 and the stemline karyotype was used as the representative karyotype for all analyses.
Flow cytometric analysis of p-glycoprotein activity
The ability of CEM and HL60 cells to expel the fluorescent pglycoprotein substrate 3,3-diethyloxa-dicarbocyanine iodide (DIOC2(3); Sigma) was measured by flow cytometry. Cells were cultured in culture medium containing 60 ng/ml DIOC2(3), and incubated at 37°C for 30 min. The cells were then pelleted and re-suspended in fresh medium in preparation for efflux study. One aliquot was placed on ice for immediate analysis of dye content. The remaining cells were incubated at 37°C for up to 90 min. Aliquots were removed every 15 min and washed in ice-cold medium before analysis of dye content. The mean fluorescence intensity of DIOC2 (3) in each individual cell was detected in fluorescence channel 1 (FL1) of the flow cytometer. The functional ability of the cells to expel DIOC2(3) was calculated as the difference in dye intensity before and after its efflux.
Assessment of bcl2/bax and topo II␣ by immunoblot analysis
Whole cell lysates were resolved by SDS-PAGE using 15% acrylamide with a 5% stacking gel as described previously. 19 Briefly, primary antibody probing was performed with mouse anti-bcl2 (1:100; Dako, Cambridge, UK), mouse anti-bax (1:40; PharMingen, San Diego, CA, USA), or rabbit anti-topo II␣ (1:1000; TopoGEN, Columbus, OH, USA). Following a washing step in 0.1% Tween in Tris-buffered saline (100 mM Tris, 150 mM NaCl, pH 7.6), horseradish peroxidase-conjugated anti-mouse (or rabbit) IgG 1 was used as the secondary antibody (Dako). Bands were visualised by the ECL-plus detection system (Amersham Life Science, Little Chalfont, UK).
Statistical analysis
All statistical analysis was carried out using Minitab version 13 (State College, PA, USA). Any difference between treatments, as determined by analyses of variance, were further characterised by the standard paired Student's t-test. Control samples were normally distributed as determined by the Shapiro-Wilk test, and parametric tests were used throughout.
Results
Preliminary experiments were performed to determine the highest concentration of etoposide that caused no significant effect on cell growth and cell cycle distribution. This was called the low concentration of etoposide (LC-etoposide), and was 0.01 M for both CEM and HL60 cells (Figure 1 ).
LC-etoposide negates the cytotoxic effect of etoposide
Apoptosis was induced in cells with a previously determined cytotoxic concentration (IC 50 ) of etoposide (0.3 M). CEM and Assessment of LC-etoposide. Cells were exposed to a range of low concentrations of etoposide (0-0.03 M). The LC-etoposide was 0.01 M, as this concentration had no significant effect on either cell proliferation or viability. Even concentrations that were mildly significant (P Ͻ 0.05) were excluded to rigorously remove the possibility of selecting out resistant clones. As an example, even though 0.015 M etoposide () had no effect on cell viability, it significantly reduced cell proliferation on days 4 and 5 (P = 0.020 and P = 0.034, respectively). Consequently, this concentration could not be considered as the LC-etoposide. Methods and results were similar for both CEM and HL60 cells, and so only those of CEM are shown. Data points represent the mean of three separate experiments, and s.ds are shown for controls, and for concentrations Ͼ0.015 M. *P Ͻ 0.05 vs controls.
Leukemia HL60 cells pre-cultured with LC-etoposide for р2 days conferred no resistance to 0.3 M etoposide (data not shown). However, this was not observed in cells pre-cultured with LCetoposide for 3 days or more. Results were essentially similar in both CEM and HL60 cells, so only data from HL60 are presented. Cells treated continuously with LC-etoposide showed no differences in cell growth or viability (%V). There was only a reduction in %V upon exposure to etoposide in the nil-highE schedule (day 4: 71.9 ± 10.6% vs 97.3 ± 0.9% in control cultures; P Ͻ 0.001), but there was no decrease in %V upon exposure to etoposide in the lowE-highE schedule (Ͼ95% at all time points) (Figure 2) .
Flow cytometric analysis indicated that the reduction in %V seen in cells on the nil-highE schedule was due to apoptosis (day 6: 19.0 ± 0.7% vs 1.2 ± 0.7% in untreated cells; P Ͻ 0.001), and direct comparison of the low-highE schedule with the nil-highE schedule showed that there was significantly less apoptosis in the former schedule (Figure 2 ).
Anti-cytotoxic effects of LC-etoposide is long-term
CEM and HL60 cells were cultured with LC-etoposide for 5 days, washed and propagated in drug-free medium, and designated the suffix '-L'. These sublines exhibited growth characteristics similar to those of their respective parental cell line.
Following a 1 week recovery period, these cells were exposed to 0.3 M etoposide. In HL60 control cells, there was a significant reduction in %V and a concomitant increase in apoptotic cells (Figure 3a) . However, these changes were not observed in HL60-L cells treated with the same concentration of etoposide (on day 4, %V: 88.1 ± 4.6% vs 92.9 ± 5.9% and %A: 1.1 ± 0.5% vs 1.5 ± 1.0%, relative to control HL60-L cells with no etoposide).
Further analysis of these cells revealed an accumulation of cells in the G2/M phase of the cell cycle (day 4: 28.7 ± 0.8% vs 15.4 ± 2.6% in cells with no etoposide; P Ͻ 0.001), and significantly reduced cell proliferation (×10 5 cells on day 4: 2.9 ± 0.7 vs 12.3 ± 1.4 in control cells; P Ͻ 0.001). Similar results were seen in CEM and CEM-L cells, which showed a 36% reduction in the ability of etoposide to induce cell kill in the latter with concomitant cell cycle perturbations ( Figure  3b ). These responses to 0.3 M etoposide were persistent in both CEM-L and HL60-L cells and still apparent after a 4 week maintenance in drug-free medium.
Reduced effect of etoposide is not a result of decreased drug sensitivity
The concentration of etoposide used in an attempt to induce cytotoxicity was increased three-fold to 0.9 M (ϷIC 90 ), to discount the possible reduction in sensitivity to drug in the CEM-L and HL60-L sublines. Results indicated that upon exposure to these higher concentrations of etoposide, there was still no significant reduction in the cell viability of both CEM-L and HL60-L at any time point (Figure 4) .
Figure 4
The effect of a continuous exposure to hyper-concentrations of etoposide on cell viability. Cells (CEM, CEM-L, HL60 and HL60-L) were cultured with etoposide (0-0.9 M) for 4 days. Data points represent the means and s.ds of three separate experiments. There were significant differences between respective cells at all concentration points; P Ͻ 0.001.
Reduced effect of etoposide is not a result of increased drug efflux
Functional efflux, as a measure of p-glycoprotein activity, was readily detected in these cell types using the dye DIOC2(3). There was no significant difference in the rate of dye efflux between the two cell types ( Figure 5 ). Similar results were also observed in HL60 with HL60-L cells (data not shown).
Reduced effect of etoposide is not a result of decreased drug-induced DNA damage
To investigate whether the clastogenic effect of etoposide was reduced in the sublines, CEM-L and HL60-L cells were incubated with etoposide for 24 h, and the frequency of SCEs assessed. Results indicated no significant difference in SCE numbers in each subline compared to the respective parental cell line (Table 2) .
Reduced effect of etoposide is not a result of decreased topo II␣ protein
To investigate whether topo II␣ protein levels were reduced in the sublines, whole cell lysates from CEM and CEM-L were analysed electrophorectically, and immunoprobed for topo
Figure 5
The functional efflux of DIOC2(3) in CEM (triangle) and CEM-L (square) cells. Data points represent the means and s.ds of three separate experiments. Table 2 The effect of a 24 h incubation of etoposide on the SCE frequency in CEM and HL60 cells and in the CEM-L and HL60-L sublines
3 ± 0.6 6.9 ± 2.1 6.3 ± 0.6 0.2 10.6 ± 3.6 10.7 ± 1.5 9.5 ± 2.6 9.7 ± 0.6 0. 4 14.9 ± 3.9 15.5 ± 0.5 14.9 ± 3.5 14. II␣. Comparative analyses of results indicated no significant differences of protein expression in the two cells (Figure 6a ).
LC-etoposide increases genetic instability without altering karyotype
The karyotype of the CEM-L and HL60-L sublines were no different from their respective parental cell line. However, there was a three-fold increase in the frequency of random structural aberrations (RSAs) in both sublines (Ϸ90% of CEM-L and HL60-L sublines vs Ϸ30% of the parental cells). These abnormalities included a reciprocal translocation between 13 and 14, and numerous unbalanced translocations involving many chromosomes. By definition, these RSAs were not seen 
LC-etoposide reduces bax protein levels
Western blot analyses were performed on whole cell extracts of all the cell lines and sublines following a cytotoxic challenge with etoposide. This revealed that bcl-2 protein levels remained unchanged in the sublines, however, there was a decreased level of bax protein in the CEM-L and HL60-L sublines compared to their respective parental cell line ( Figure  6b ).
LC-etoposide does not negate the cytotoxic effect of cisplatin
To determine whether the pre-culture to LC-etoposide could provide a protective effect against other cytotoxics, CEM-L and HL60-L cells were cultured with 10 M cisplatin for 4 days (ϷIC 50 ). Results showed no difference in %V in these cell lines compared to their respective parental cell lines ( Figure  7 ).
Induction of anti-cytotoxic effect is specific to topo II inhibitors
To further investigate whether the observations with etoposide was specific only to this class of agent, another topo II inhibitor doxorubicin, and a non-topo II-specific inhibiting agent cisplatin, were investigated in similar experiments to those reported in the previous sections. In summary, cells were precultured with a low concentration of either drug, before culturing with cytotoxic concentrations of etoposide or cisplatin. Preliminary experiments defined the low concentration of doxorubicin and cisplatin to be 0.02 M and 0.2 M respectively (data not shown). Table 3 highlights the differences in cytotoxic response in HL60 cells exposed to the 10 distinct drug schedules studied, and tabulates the cell number and cell viability on day 6.
Figure 7
Effect of LC-etoposide on the cytotoxic effect of 10 M cisplatin. Columns represent data for day 4 in CEM and CEM-L (shaded bars) and HL60 and HL60-L (unshaded bars) cells. Data points represent the means and s.ds of at least three separate experiments, and P values are shown as calculated by paired Student's t-test. Table 3 HL60 cells were cultured for 6 days according to one of 10 schedules (A-J)
Days
Parameter on day 6 a Difference P Ͻ 0.001; b Difference P Ͻ 0.001. Cells were initially cultured for 3 days at a low concentration of etoposide (LE), doxorubicin (LD) or cisplatin (LC), before culturing with a cytotoxic concentration of etoposide (E) or cisplatin (C) for a further 3 days. Data show the cell number and viability on day 6 for each drug schedule, and represent the means and s.ds of at least three separate experiments.
Discussion
This study was undertaken to investigate the effect of etoposide in a panel of leukaemic cell lines, with particular interest in the effect of a low concentration of drug. We confirmed that etoposide was a potent clastogenic agent in cell lines, increasing the frequency of SCEs in a dose-dependent manner. The most significant finding of this study was that the culture of cells for more than 3 days with a low concentration of etoposide that had no effect on cell growth parameters caused alterations in apoptosis in CEM and HL60 cells. These changes were both persistent and sustained.
In the first part of this investigation, we showed that the preculture of CEM and HL60 cells with LC-etoposide conferred resistance when cells were subsequently exposed to cytotoxic concentrations of etoposide. Crucially, these induced changes were persistent, as LC-treated cells maintained in drug-free medium for 4 weeks still showed resistance to cytotoxic concentrations of etoposide. Also, these cells did not simply have reduced sensitivity to etoposide, as hyper-concentrations of drug also had no significant effect on cell viability.
In vitro resistance to anti-neoplastic drugs, such as etoposide, has commonly been attributed to elevated expression of the ATP-binding-cassette super-family of trans-membrane transporter proteins, 22 and may have explained the reduced drug effect observed in our cells. This family consists of many members, however, the specific efflux of etoposide is mediated primarily by p-glycoprotein (Pgp), 23, 24 and as a consequence, its capacity to efflux the Pgp-specific polymethine dye DIOC2(3) was examined in our cell lines and shown to be identical in all respective cells. The substitution of DIOC2(3) with carboxyfluorescein diacetate, a specific substrate for the multidrug resistance protein, also showed the rate of efflux by this pump to be similarly unchanged in the sublines (data not shown). In addition to these efflux pathways, several other mechanisms have also been described in cell lines, one of which involves the reduced level and activity of the enzyme topo II. 25 Subsequently, levels of this enzyme were assessed in these sublines, and shown to be no different from the parental control cells. The observation that there was no change in cell cycle dynamics, rate of proliferation or cell viability at any time during culture with LC-etoposide suggested that this pre-exposure was not simply selecting out a resistant clone. Indeed, drug-resistant cell lines are usually developed by repeated exposure to stepwise increasing suboptimal concentrations of drug over a prolonged period of many months. 25, 26 The cytotoxic effect of etoposide in cells is dependent upon the intracellular concentrations of free drug, particularly the concentrations within the nucleus where it exerts its effect. This is generally dependent upon the duration of exposure of the cells to drug, and upon the extracellular drug concentrations. Clinically, a typical intravenous administration of 100 mg/m 2 etoposide over 2 h in vivo, results in a peak plasma etoposide concentration of 15 g/ml (Ϸ25 M), which falls to 1 g/ml (Ϸ2 M) after 24 h. However, intracellular etoposide concentrations are invariably much lower than these extracellular plasma concentrations. 27 Indeed, Zhou et al 28 showed intracellular etoposide concentrations in a patient receiving an equivalent dose of etoposide to that described above peaking at the end of infusion (0.4 g/ml Ϸ0.7 M), before rapidly declining to below their limit of quantification by 24 h (Ͻ0.01 g/ml Ϸ0.02 M). Intracellular concentration in patients receiving more prolonged etoposide administration would be considerably lower than these peak levels. The very low concentrations of etoposide used in our studies are therefore clinically relevant.
To further ascertain the possible mechanism of reduced drug sensitivity in the sublines, the frequency of SCEs induced by culture with etoposide was assessed in CEM-L and HL60-L. Our results showed that the clastogenecity of etoposide was similar to those levels observed in the parental cell lines. This indicated that the change in the cellular response to subsequent exposure to etoposide in these sublines, must lay downstream of drug/DNA interactions.
We next investigated whether this change in apoptotic response to etoposide in the CEM-L and HL60-L sublines was a consequence of gross alterations to the genome, by means of cytogenetic analysis of these cells. Results revealed no consistent changes in the karyotype of CEM-L and HL60-L compared to their parental cells. However, there was a three-fold increase in the number of RSAs in these cells. By definition, RSAs are chromosomal abnormalities present in only one or two metaphase cells, which do not affect the definition of the karyotype. There were numerous anomalies seen in our samples, which could not be completely quantified. They involved many regions on a number of chromosomes, and among them, abnormalities were seen on chromosomes 11, 17 and 19. Therefore, the frequencies of these aberrations were used mainly as an indicator of the general genetic instability of both the CEM-L and HL60-L sublines.
Instead of inducing a cytotoxic effect in the CEM-L and HL60-L sublines, etoposide caused a cytostatic response with a block at the G2/M boundary of the cell cycle coupled with a significant decrease in cell number. This etoposide-induced block has been reported previously, and usually precedes cell death by apoptosis, 29 and although we showed a similar protracted G2/M block, no apoptosis was observed. These results when considered together with the increased genetic instability in the sublines, lead us to measure levels of bax, a key pro-apoptotic protein, in these cells after a cytotoxic challenge to etoposide. 30 These levels were reduced in CEM-L and HL60-L cells relative to CEM and HL60 cells. Since it is generally accepted that it is the ratio of bcl-2 family pro-apoptotic proteins to anti-apoptotic proteins that determines the sensi-tivity of leukaemic cells to apoptosis, 31 ,32 the levels of bcl-2 were also assessed and shown to be unchanged in these cells. Both CEM-L and HL60-L cells maintained their sensitivities to cisplatin-induced apoptosis despite reduced levels of bax. However, there have been reports of mechanisms not involving these members of the bcl-2 family of proteins in cisplatininduced apoptosis. [33] [34] [35] A resistance to cellular apoptosis could not be reproduced through pre-incubation with low concentrations of cisplatin. However, resistance to etoposide following pre-incubation with doxorubicin, another topo II inhibitor, was seen. This suggested the involvement of topo II in this model of drug resistance. Cisplatin exerts its cytotoxic effect by forming drug-DNA adducts impartially throughout the genome, that interfere with replication. 36 In contrast to the more indiscriminate damage caused by cisplatin, the DNA sequence specificity of topo II ensures the existence of favourable sites in DNA to which etoposide and doxorubicin can interact and cause anomalies. Importantly, these preferred sites tend to traverse regions that are rich in genes, 37 and as a result, topo II inhibitor/DNA interactions can potentially affect many genes. 6 Studies have demonstrated an association between DNA topo II cleavage sites and translocation breakpoints/aberrations, 38, 39 suggesting that translocation mechanisms may involve DNA topo II-mediated chromosomal breakage before formation of translocations when the breakage is repaired. One recognised cleavage site of topo II is positioned near the bax gene on chromosome 19q.
14 Thus, speculatively, the higher frequency of RSAs and the increased level of DNA instability present in CEM-L and HL60-L cells may have involved disruption to this particular region of the chromosome, causing a down-regulation of bax function, and an increased survival advantage over other cells. Indeed, the down-regulation of bax mRNA has been shown previously to be a mechanism responsible for etoposide-induced resistance in drug-resistant clones. 40 Parenthetically, LC-etoposide also lowered the differentiation capability in K562 cells (unreported data), highlighting possible disruption to other genes in these cells.
In summary, we have shown for the first time that exposure to low concentrations of etoposide for more than 3 days has no effect on cell growth parameters, but can disrupt cellular processes without inducing a consistent change in karyotype. The frequency of genetic aberrations is an established indicator of genetic damage, and is dependent on etoposide concentration. 12 Generally, cells with damaged DNA are either repaired, or undergo apoptosis. However, our observations showed that the amount of genetic damage induced by LCetoposide was sufficient to cause a change in the phenotype, but not enough to affect cell proliferation or to trigger apoptosis. Crucially, these cells would appear to have evaded repair mechanisms, as some of the DNA damage induced during the initial drug exposure had persisted. This could, theoretically, contribute to the development of secondary leukaemias. In conclusion, our studies highlight the dual nature of etoposide, and suggest that its leukaemogenic effect may be inseparable from the desired effect of anti-tumour activity.
